The majority of the evidence points towards PPARγ ligandssuppressing tumourgenesis, for example, the receptors' ligands inhibit thegrowth of xenografts of many of the aforementioned tumours in vivo [35].However, in colon cancer, the beneficial role for PPARγ agonists iscontroversial [57]. Here, PPARG is linked to malignant colon neoplasm.